Trial Profile

Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard-of-care Therapy)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 26 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 May 2024 Results up to 7.4 years from the long-term access programme presented at the 120th International Conference of the American Thoracic Society
26 Feb 2024 Long term safety results of Mepolizumab presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
14 Feb 2024 The protocol has been amended as above-1) Number of actual number of patients has been changed from 101 to 100. 2) Primary endpoint has been amended.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com